Hennigsdorf

EQS-News: Liberation from renal replacement therapy and early initiation to be supported by the kidney function biomarker Proenkephalin A 119-159 (penKid)

Retrieved on: 
Sunday, December 18, 2022

PenKid identified as a promising kidney function biomarker to support future precision medicine approaches for RRT-dependent AKI.

Key Points: 
  • PenKid identified as a promising kidney function biomarker to support future precision medicine approaches for RRT-dependent AKI.
  • Hennigsdorf, Germany, December 15, 2022 - The diagnostic company SphingoTec GmbH (SphingoTec) announces first data on the kidney function biomarker penKid as a promising tool in supporting early initiation and liberation from RRT (1).
  • Proenkephalin A 119–159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial.
  • Scientific evidence shows that penKid also reflects kidney function in children, representing a potential biomarker for pediatric AKI.

EQS-News: Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)

Retrieved on: 
Sunday, November 27, 2022

Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.

Key Points: 
  • Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.
  • The critical state is currently diagnosed by standard-of-care biomarkers when 50% of the kidney function is already lost (1).
  • PenKid addresses these pitfalls, offering an earlier and more precise determination of kidney function in acute and critical care settings (2).
  • Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study.

DGAP-News: Interdepartmental testing of the kidney function biomarker penKid in routine care at Heidelberg University Hospital and the Heidelberg Kidney Center

Retrieved on: 
Friday, August 26, 2022

Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.

Key Points: 
  • Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.
  • PenKid is a proposed biomarker for real-time kidney function that potentially closes on the gaps of the standard diagnostic procedures.
  • This includes the normal, the intermediate care (IMC), the nephrology, and the intensive care units (ICU) of both clinics in Heidelberg.
  • This routine use of penKid on a centralized level in the hospital drives innovation on multiple wards such as nephrology, ICU and IMC.

DGAP-News: Endothelial function biomarker bioactive Adrenomedullin (bio-ADM) enables triage of sepsis patients in the emergency department

Retrieved on: 
Monday, August 1, 2022

Unfortunately, sepsis is difficult to diagnose and treat because it has a high range of forms and intensities.

Key Points: 
  • Unfortunately, sepsis is difficult to diagnose and treat because it has a high range of forms and intensities.
  • In ED, it is still difficult to identify sepsis patients early, and assigning the correct further treatment is thus challenging.
  • Lundberg OHM, Rosenqvist M, Bronton K, Schulte J, Friberg H, Melander O (2022) Bioactive adrenomedullin in sepsis patients in the emergency department is associated with mortality, organ failure, and admission to intensive care.
  • SphingoTec's proprietary biomarker portfolio includes bioactive Adrenomedullin (bio-ADM), a biomarker for real-time assessment of endothelial function in conditions like sepsis, and Proenkephalin (penKid), a biomarker for real-time assessment of kidney function.

DGAP-News: SphingoTec appoints Jörg Menten as CEO to accelerate commercialization and global growth

Retrieved on: 
Thursday, June 30, 2022

SphingoTec appoints Jrg Menten as Chief Executive Officer (CEO) as from July 1, 2022 to drive the commercialization and scale its diagnostic business.

Key Points: 
  • SphingoTec appoints Jrg Menten as Chief Executive Officer (CEO) as from July 1, 2022 to drive the commercialization and scale its diagnostic business.
  • Hennigsdorf/Berlin, Germany, June 30, 2021 Diagnostics company SphingoTec GmbH (SphingoTec) today announced that Jrg Menten was appointed CEO of SphingoTec effective of July 1, 2022.
  • Jrg Menten is a highly skilled senior executive with a long-standing track record of leadership positions in the global healthcare industry.
  • On behalf of the Advisory Board I welcome Jrg Menten in his new capacity as CEO of SphingoTec.

DGAP-News: The Biomarkers bio-ADM and DPP3 Complement Post-Cardiac Surgery Diagnostics to Early Detect Organ Failure

Retrieved on: 
Friday, April 1, 2022

Bio-ADM may help identify patients with an increased risk of developing prolonged vasopressor dependence and prolonged ICU stay after cardiac surgery.

Key Points: 
  • Bio-ADM may help identify patients with an increased risk of developing prolonged vasopressor dependence and prolonged ICU stay after cardiac surgery.
  • Scientists from the Radboud University Medical Center have analyzed the predictive value of bio-ADM and DPP3 for short-term outcomes in a prospective study in cardiac surgery patients.
  • Compromised hemodynamics after surgery triggers the release of the hormone bio-ADM, a key regulator of endothelial barrier function and vascular tone.
  • Not surgery-induced and persistently high concentration of DPP3 signals impaired tissue perfusion and high risk for organ failure (5).

DGAP-News: SphingoTec and Rivaara Labs Close Exclusive Distribution Agreement for Point of Care Diagnostics in India

Retrieved on: 
Thursday, March 17, 2022

Hennigsdorf, Germany and Mumbai, India, March 17, 2022 - The diagnostic company SphingoTec GmbH (SphingoTec) and Rivaara Labs Pvt Ltd. (Rivaara) today announced that they have entered into a multi-year distribution agreement for the commercialization of SphingoTec's point of care diagnostic solutions in the Indian subcontinent.

Key Points: 
  • Hennigsdorf, Germany and Mumbai, India, March 17, 2022 - The diagnostic company SphingoTec GmbH (SphingoTec) and Rivaara Labs Pvt Ltd. (Rivaara) today announced that they have entered into a multi-year distribution agreement for the commercialization of SphingoTec's point of care diagnostic solutions in the Indian subcontinent.
  • Under the terms of the agreement, Rivaara will have the exclusive right to market and distribute SphingoTec's point of care tests for innovative biomarkers in the Indian subcontinent.
  • Rivaara Labs Pvt Ltd. ("Rivaara", Mumbai, India) is harnessing the power of Molecular diagnostics to bring disruptive, affordable, and innovative need-based diagnostic solutions to India.
  • The aim is to develop a strong network of specialized Molecular Diagnostics labs, market novel point of care solutions and build a best-in-class national reference lab.

DGAP-News: Proenkephalin (penKid) sheds light on the diagnostic blind spots in assessing acute kidney injury in children

Retrieved on: 
Tuesday, March 15, 2022

For children burdened with life-threatening acute kidney injury (AKI) there are no reliable diagnostics to assist the management of pediatric AKI.

Key Points: 
  • For children burdened with life-threatening acute kidney injury (AKI) there are no reliable diagnostics to assist the management of pediatric AKI.
  • AKI is mostly diagnosed too late for successful intervention which leads to steep mortality rates and chronic kidney disease (1,2).
  • Bennett MR, Nehus E, Haffner C, Ma Q, Devarajan P. Pediatric reference ranges for acute kidney injury biomarkers.
  • Circulating Proenkephalin, Acute Kidney Injury, and Its Improvement in Patients with Severe Sepsis or Shock.

DGAP-News: SphingoTec Appoints Jörg Menten to Leadership Team as Chief Commercial Officer to Drive New Business Growth

Retrieved on: 
Monday, November 29, 2021

SphingoTec expands leadership team to facilitate scaling of its fast-growing diagnostics business.

Key Points: 
  • SphingoTec expands leadership team to facilitate scaling of its fast-growing diagnostics business.
  • Jrg Menten will lead the company's commercial efforts and drive expansion into global markets.
  • Hennigsdorf/Berlin, Germany, November 29, 2021 - Diagnostics company SphingoTec GmbH ("SphingoTec") today announced the appointment of Jrg Menten as its Chief Commercial Officer.
  • "We are committed to bringing personalized medicine to critical care," said Dr. Andreas Bergmann, Chief Executive Officer and founder of SphingoTec.

DGAP-News: SphingoTec's innovative biomarkers to enable personalized medicine in septic organ failure

Retrieved on: 
Thursday, September 9, 2021

SphingoTec's biomarkers for assessing organ function in real-time help guide clinical decision making by providing patient-specific information.

Key Points: 
  • SphingoTec's biomarkers for assessing organ function in real-time help guide clinical decision making by providing patient-specific information.
  • In the oral presentation on the "Properties of Proenkephalin in septic acute kidney injury", Dr. med.
  • In the presentation "Biomarker-guided Approach for the Treatment of Septic Shock - Precision Medicine in the AdrenOSS-2", Prof. Dr. med.
  • Tobias Schrholz from the Uniklinik RWTH Aachen will show a closer look at the steps taken to achieve precision medicine in septic organ failure.